Pharmaron Beijing logo

Pharmaron Beijing(SEHK) 3759

Market CapHK$50.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+63%
5 Year-60%
1 Year+21%
1 Month-5%
HK$27.86
-2.31%
-0.66Today
Pharmaron Beijing last closing stock price
MetricPriceDate
Last closeHKD 27.862026-10-14
Pharmaron Beijing stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.37%HKD 32.162026-10-07
1 month-5.3%HKD 29.422026-09-14
3 month+11.62%HKD 24.962026-07-16
Year to date+42.22%HKD 19.592025-12-31
1 year+21.03%HKD 23.022025-10-14
3 year+38.26%HKD 20.152023-10-13
5 year-60.02%HKD 69.692021-10-15
Since inception+63.1%HKD 17.492019-11-28

Pharmaron Beijing Financials at a Glance

Market Cap

HK$50.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥15.08B

Net Income (TTM)

CN¥1.71B

EPS (TTM)

HK$1.06

P/E Ratio

26.16

Dividend

HK$0.23

Beta (Volatility)

-0.02 (Low)

Price

HK$27.86

Volume

8,471,729

Open

HK$29.40

Previous Close

HK$28.52

Daily Range

HK$27.54 - HK$29.40

52-Week Range

HK$14.45 - HK$34.86

Estimated Earnings Date

Oct 22, 2026

3759 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd. is a leading pharmaceutical research and development service platform operating globally, including North America, Europe, and Asia. The company specializes in providing comprehensive services across various segments, including laboratory services, clinical research, and macromolecule therapy.

Products and Services
  • Laboratory chemistry and biological science services
  • Clinical research and development services
  • Macromolecule and cell gene therapy services
Growth Outlook
  • Revenue increased to CNY 3.99 billion in Q2 2026
  • Net income rose to CNY 413 million in Q2 2026
  • Strong demand for R&D services supports future growth
Financial Highlights
  • Trailing twelve-month revenue of CNY 15.4 billion
  • Net profit margin of 11.27% for the TTM period
  • Operating income ratio of 13.23% in Q2 2026
Pharmaron Beijing Co., Ltd. has established itself as a key player in the biotechnology industry, offering a wide range of services that cater to the evolving needs of pharmaceutical companies. The company's diverse service offerings, including laboratory services and clinical research, position it well to capitalize on the growing demand for R&D in the healthcare sector. Recent financial performance indicates a robust growth trajectory, with a significant increase in revenue and net income in the latest quarter. The revenue of CNY 3.99 billion in Q2 2026 reflects a strong operational performance, while the net profit margin of 11.27% demonstrates effective cost management and operational efficiency. The company's focus on innovation and technology development is expected to drive future growth, particularly in the areas of macromolecule and cell gene therapy services. As the global pharmaceutical market continues to expand, Pharmaron is well-positioned to leverage its expertise and resources to meet the increasing demand for comprehensive R&D services.
AI Generated • Oct 12, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

25,088

CEO

Bo Liang Lou, PhD

Website

www.pharmaron.cn

Headquarters

Beijing, BE 100176, CN

3759 Financials

Key Financial Metrics (TTM)

Gross Margin

33.27%

Operating Margin

13.49%

Net Income Margin

11.27%

Return on Equity

10.96%

Return on Capital

10.44%

Return on Assets

5.92%

Earnings Yield

3.82%

Dividend Yield

0.83%

Payout Ratio

31.96%

Stock Overview

Market Cap

HK$50.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.83B

Volume

8.47M

Avg. Volume

8.33M

Financials (TTM)

Gross Profit

CN¥5.06B

Operating Income

CN¥2.10B

EBITDA

CN¥2.57B

Operating Cash Flow

CN¥2.95B

Capital Expenditure

-CN¥2.90B

Free Cash Flow

CN¥50.01M

Cash & ST Invst.

CN¥2.45B

Total Debt

CN¥6.95B

Pharmaron Beijing Performance Analysis

Pharmaron Beijing annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 11,920,760,99332.9%
20232023-12-31CNY 12,726,149,4306.8%
20242024-12-31CNY 13,309,687,9404.6%
20252025-12-31CNY 15,250,581,61314.6%
Pharmaron Beijing sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.3%
Q42025-12-3110.1%
Q12026-03-31-10.2%
Q22026-06-3012.8%
Pharmaron Beijing annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.90-18.2%
20232023-12-31CNY 1.0010.7%
20242024-12-31CNY 1.1010.0%
20252025-12-31CNY 1.02-7.1%
Pharmaron Beijing sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3013.6%
Q42025-12-3120.0%
Q12026-03-31-40.0%
Q22026-06-3027.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥4.00B

+19.7%

Gross Profit

CN¥1.24B

+8.3%

Gross Margin

31.01%

N/A

Market Cap

HK$50.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$2.03M

N/A

Employees

25,088

N/A

Net Income

CN¥413.07M

+4.4%

EBITDA

CN¥889.02M

+15.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥2.45B

+13.5%

Total Debt

CN¥6.95B

+23.9%

Accounts Receivable

CN¥3.79B

+22.5%

Inventory

CN¥1.93B

+48.2%

Long Term Debt

CN¥2.27B

-50.7%

Short Term Debt

CN¥4.68B

+366.9%

Return on Assets

5.92%

N/A

Return on Invested Capital

10.14%

N/A

Free Cash Flow

-CN¥297.85M

-593.0%

Operating Cash Flow

CN¥499.30M

-10.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,803.85-0.00%
^DJIDJI
$51,687.96-0.00%
^IXICNASDAQ
$27,201.84-0.00%
BTCBitcoin
$83,069.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
BACBank of America
$50.97-5.55%
CRWVCoreWeave
$65.12-16.32%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$41.84+11.81%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$112.65-11.70%

Questions About 3759

What is the current price of Pharmaron Beijing?

Pharmaron Beijing is trading at HK$27.86 per share.

What is the 52-week range for Pharmaron Beijing?

Over the past 52 weeks, Pharmaron Beijing has traded between HK$14.45 and HK$34.86.

How much debt does Pharmaron Beijing have?

As of the most recent reporting period, Pharmaron Beijing reported total debt of CN¥8.04B.

How much cash does Pharmaron Beijing have on hand?

Pharmaron Beijing reported CN¥1.82B in cash and cash equivalents in its most recent financial results.

What is Pharmaron Beijing’s dividend yield?

Pharmaron Beijing currently has a dividend yield of 0.83%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services